
Merck has launched the first new drug in a class of antibiotics in the UK in almost 15 years, becoming …

Celgene has elected pharma veteran Michael Bonney to join its board of directors. Bonney served as chief executive and board …

Cubist has followed-up its successful European approval for a new antibiotic by winning an endorsement by the US FDA. The …

Hot on the heals of its Cubist buyout Merck has confirmed the acquisition of OncoEthix, a Swiss based firm which …

Merck has purchased US antibiotics maker Cubist in a deal valued at $9.5 billion. The acquisition values Cubist at around …

US biopharma firm Cubist Pharmaceuticals has named Robert Perez as its chief executive and who will begin the role from …
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer

